
Consumer panel asks Apple, Croma to refund customer's iPhone cost over microphone defect
Both the manufacturer and the seller are 'jointly and severally liable for the defective product', the commission said in the order passed earlier this month, as the two companies failed to resolve the defect in the device purchased by the customer (now deceased).
Mumbai, Jul 20 (PTI) A consumer commission here has directed Apple India and Croma to refund an i-Phone cost of Rs 65,264 to the legal heirs of a customer for failing to resolve a microphone defect in the device, holding the two companies deficient in service.
It further ruled that the seller (Croma) too cannot escape liability merely by stating the 'defect is attributable to the manufacturer'.
'Once the product was sold through their outlet, they assumed responsibility for ensuring that the product was free from defects and serviceable,' the commission noted.
It said the 'principle of vicarious liability squarely applies', as the seller stands in a position of trust and derives commercial benefit from the sale.
The complainant purchased an iPhone 11 for Rs 65,264 from a Croma store in Mumbai on June 4, 2021.
Shortly after the purchase, the device developed an issue as the speakerphone function was not working during calls, with specifically 'no speech from mic'.
The complainant approached Apple's authorised service centre, but repairs were denied on the grounds of 'unauthorized modifications in the device,' rendering it ineligible for warranty service.
Despite repeated complaints and emails, the opposite parties failed to address the grievance, following which the complainant approached the commission.
During the course of proceeding, the customer passed away, but the complaint was continued by his legal heirs.
The Apple India Private Limited, in its response, admitted the purchase and the issue with the microphone. But it reiterated that the device had unauthorised modifications, voiding the warranty.
Infiniti Retail Limited (Croma) failed to appear and was proceeded against ex-parte.
The commission, after perusal of documents on record, held that Apple failed to specify exactly which term or condition of the warranty was breached by the complainant.
'Merely referring clauses of warranty terms and condition cannot be sufficient to attribute the particular defect as certain unauthorized modification or damage to software,' it noted.
The commission concluded that documents and evidence brought on record are sufficient to ascertain the defect in goods coupled with deficiency in service provided by the opposite parties.
It ruled that both the manufacturer and the seller are 'jointly and severally liable for the defective product'.
The commission directed both the opposite parties to refund the iPhone cost of Rs 65,264, along with a 6 per cent interest per annum from the date of the complaint (August 6, 2021) until the date of actual payment.
The two companies were also directed to pay Rs 15,000 as compensation for mental agony and Rs 2,000 for legal expenses to customer's family. PTI AVI GK
This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
43 minutes ago
- Time of India
Brookfield, EQT Close In on Gland Pharma, but Rising Stock a Pain
Live Events Buyout groups Brookfield and EQT are in active discussions to buy Hyderabad-based Gland Pharma, a contract development and manufacturing organisation (CDMO) and injectables company, from China's Fosun Group in what could become one of the largest buyouts of the year in the segment, said people in the know. However, the galloping share price of Gland is a potential deal two private equity groups have been shortlisted after the initial round of bids earlier this such as CVC Capital Partners are also exploring a deal, said the people cited. Warburg Pincus is said to be weighing its options before taking a call, they Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 currently owns 51.8% of Gland, having pared its stake over the years. Market capitalisation has shot up to Rs 32,964.47 crore with the Gland Pharma stock appreciating 10% in the year to date in anticipation of a transaction. It closed Friday at Rs 2,000. In the past month alone, it has shot up 16%. The Fosun stake alone would require a payout of Rs 17,141.28 crore ($1.9 billion).Change of control will involve an open offer for an additional 26% of the company from minority shareholders, making it a much larger transaction. If the open offer is fully subscribed, it would translate to a Rs 25,711 crore ($3 billion) acquisition at current and Gland didn't respond to queries. Brookfield and EQT declined to investors are of the view the stock is overpriced and are interested only at a discount to the current level. 'There are macro headwinds because of industry glut and geopolitics,' said one of the people cited. 'Fosun has to decide if it is okay to sell at a significantly lower price.'This factor could be a deal breaker, analysts said. 'At this level, the process looks tough,' said another industry official. Fosun at various times in recent years, renewed its search for a strategic or financial deal for Gland Pharma. The company ran a full sale process last year but aborted it, only to revive plans earlier this summer, mandating Morgan Stanley and UBS. Mint was first to report that PE interest in Gland had revived in in 1978 by PVN Raju, Gland Pharma develops and manufactures generic injectables for use in nearly 90 countries on five continents, with a focus on the Indian and US markets. As with other Chinese companies, Fosun has faced regulatory issues in India due to the frosty relationship between the two countries. Even its entry into India faced significant delays with deal contours needing tweaks to comply with FDI norms. Some experts said Fosun sees the timing as ideal for an exit. But with no success for years, Fosun has been selling down its shares in the public markets through block deals. Last year, it sold about 6% for ₹1,750 crore. 'The incremental growth for the company's base business in the US is likely to come at the cost of margins,' said Shyam Srinivasan of Goldman management is expecting Cenexi Group — a French injectables and CDMO company Gland acquired in 2023 — to break even by the December quarter. Gland has a toehold in Europe through Cenexi, but rebooting the organisation and its product mix has been analysts said Gland has a sound track record and its future prospects may attract buyers.A veteran industry expert said Gland Pharma has a 'strong compliance history' and its manufacturing quality is impeccable. Plus, a surge in demand is seen for large injectable capacities across the world, making it a good fit. Another strong push for Gland Pharma is the explosive growth in glucagon-like peptide-1(GLP-1) drugs for weight loss and diabetes. Novo Nordisk's Wegovy (semaglutide) is set to go off patent early next year in India and Canada, leading to a burst of generic variants expected to enter the market. This is likely to offset the current overcapacity of injectable assets around the world. Trade tensions between the US and China are adding to the interest in Indian contract manufacturing players for steady supplies. 'Although we have not seen any meaningful switching from China yet, such opportunities cannot be ruled out in the future,' an industry executive is also preparing for a larger play in the biologics business, focusing on expanding its biosimilar and biologic CDMO segment.'The company's collaboration with DRL (Dr Reddy's) and discussions with Henlius (of China) are progressing well, with revenue generation from DRL business expected from FY26,' it said in the presentation.


Indian Express
an hour ago
- Indian Express
Two new campuses coming up, Ambedkar University set to shift from Kashmere Gate site
With two new campuses under construction in Northwest Delhi's Dheerpur and Rohini, Ambedkar University Delhi (AUD) is set to relocate from its heritage campus in Kashmere Gate. While the Dheerpur campus, spanning 4.95 acres, is being developed at a cost of Rs 1,199.02 crore, the Rohini campus, spread across 20 acres, will be set up for a cost of Rs 1,107.56 crore, The Indian Express has learnt. Both projects received statutory clearances in 2022, and the construction is underway. Vice-Chancellor Anu Singh Lather said the move was necessitated by infrastructural limitations and long-term maintenance costs at the existing site. 'The university building that we are functioning out of is a very old heritage building. We have maintained it well, but we will have to move out of here soon,' said Lather. 'It will take at least a couple of years for the construction of the new campuses to end and for us to relocate.' The current campus at Lothian Road in Kashmere Gate sits on a 3-acre site housing a 400-year-old building complex. According to the university's website, it has 'well-stocked libraries, reading rooms, online journals and computer labs,' as well as 'classrooms equipped with audio-visual equipment and WiFi connectivity'. Hostel facilities are available only for women. In addition to Kashmere Gate, AUD has been operating a 6.5-acre campus in Karampura on Shivaji Marg since 2016-17. Originally housing Deen Dayal Upadhyaya College and before that Shivaji College, the Karampura campus has been retrofitted with modern infrastructure. 'The Karampura campus has all the facilities that the Kashmere Gate campus have — technology-enabled AC classrooms, library, computer labs, student activity areas, playgrounds and cafeteria,' the university website states. Currently, over 800 students study at Karampura campus, which is also home to the School of Global Affairs (since 2018), and is expected to house the School of Vocational Studies and the School of Law and Governance in the coming years. A training kitchen and restaurant have also been set up for students of tourism and hospitality programmes. Established in 2008 by the Delhi government, AUD focuses on the humanities and social sciences and is expanding to accommodate growing academic and infrastructural needs.


Economic Times
an hour ago
- Economic Times
Stock Radar: M&M likely to break out from 1-year consolidation range; time to buy?
Mahindra & Mahindra Ltd (M&M), part of the automobile industry, has been consolidating in a range for almost a year now and chart patterns suggest that a breakout is likely in the near term traders can look to buy stock now or on dips for a possible target of Rs 3,650 in the next 2-4 months, suggest automobile stock hit a high of Rs 3,276 on February 10, 2025. However, the stock has remained confined in a range where Rs